

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

2095 Selected Articles from This Issue

EDITORIAL

2097 Twentieth Anniversary of *Molecular Cancer Therapeutics: A Vision for the Future*
Beverly A. Teicher

MCT FIRST DISCLOSURES

- 2098 **Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages**
Bryan D. Smith, Michael D. Kaufman, Scott C. Wise, Yu Mi Ahn, Timothy M. Caldwell, Cynthia B. Leary, Wei-Ping Lu, Gege Tan, Lakshminarayana Vogeti, Subha Vogeti, Breelyn A. Wilky, Lara E. Davis, Maitreyi Sharma, Rodrigo Ruiz-Soto, and Daniel L. Flynn
- 2110 **A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer**
Jiaojiao Deng, Sophia B. Chernikova, Yuelong Wang, Mirna L. Rodriguez, Stephanie J. Andersen, Maxine C. Umeh-Garcia, Bryanna O. Godfrey, Saman S. Ahmadian, Wolf-Nicolas Fischer, Kerry J. Koller, Bernd Jandeleit, Gordon M. Ringold, and Melanie Hayden Gephart

REVIEW

2117 **Synthetic Lethality in Ovarian Cancer**
Akshaya Chandrasekaran and Kevin M. Elias

SMALL MOLECULE THERAPEUTICS

2129 **ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts**
Andrew M. Baschnagel, Jacob H. Elnaggar, Haley J. VanBeek, Ashley C. Kromke, Justin H. Skiba, Saakshi Kaushik, Lindsey Abel, Paul A. Clark, Colin A. Longhurst, Kwangok P. Nickel, Ticiania A. Leal, Shuang G. Zhao, and Randall J. Kimple2140 **CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition**
Mitchell G. Lawrence, Laura H. Porter, Nicholas Choo, David Pook, Jeremy P. Grummet, Carmel J. Pezaro, Shahneen Sandhu, Susanne Ramm, Jennii Luu, Andrew Bakshi, David L. Goode, Elaine Sanij, Richard B. Pearson, Ross D. Hannan, Kaylene J. Simpson, Renea A. Taylor, Gail P. Risbridger, and Luc Furic2151 **SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents**
Jessica Gartrell, Marcia Mellado-Largarde, Michael R. Clay, Armita Bahrami, Natasha A. Sahr, April Sykes, Kaley Blankenship, Lauren Hoffmann, Jia Xie, Hyekyung P. Cho, Nathaniel Twarog, Michele Connelly, Koon-Kiu Yan, Jiyang Yu, Shaina N. Porter, Shondra M. Pruett-Miller, Geoffrey Neale, Christopher L. Tinkle, Sara M. Federico, Elizabeth A. Stewart, and Anang A. Shelat2166 **The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria**
Christopher W. Schultz, Grace A. McCarthy, Teena Nerwal, Avinoam Nevler, James B. DuHadaway, Matthew D. McCoy, Wei Jiang, Samantha Z. Brown, Austin Goetz, Aditi Jain, Valerie S. Calvert, Vikalp Vishwakarma, Dezhen Wang, Ranjan Preet, Joel Cassel, Ross Summer, Hooria Shaghghi, Yves Pommier, Simone A. Baechler, Michael J. Pishvaian, Talia Golan, Charles J. Yeo, Emanuel F. Petricoin, George C. Prendergast, Joseph Salvino, Pankaj K. Singh, Dan A. Dixon, and Jonathan R. Brody2177 **Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, *BRAF*-mutated Urothelial Carcinoma**
Paul Rossman, Tanja S. Zabka, Audrey Ruple, Dietrich Tuerck, José A. Ramos-Vara, Liling Liu, Rodrigo Mohallem, Mark Merchant, Jacqueline Franco, Christopher M. Fulkerson, Ketaki P. Bhide, Matthew Breen, Uma K. Aryal, Elaine Murray, Noel Dybdal, Sagar M. Utturkar, Lindsey M. Fourez, Alexander W. Enstrom, Deepika Dhawan, and Deborah W. Knapp

TABLE OF CONTENTS


- 2189** **Translational Strategies for Repotrectinib in Neuroblastoma**
Tara J. O'Donohue, Glorymar Ibáñez, Diego Ferreira Coutinho, Audrey Mauguen, Armaan Siddiquee, Nestor Rosales, Paul Calder, Andoyo Ndengu, Daoqi You, Matthew Long, Stephen S. Roberts, Andrew L. Kung, and Filemon S. Dela Cruz
- 2198** **The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G₁ Cell-Cycle Arrest through c-Myc Downregulation**
Yuchen Jiang, Xia Peng, Yinchun Ji, Yang Dai, Yanfen Fang, Bing Xiong, Wenming Ren, Youhong Hu, Yi Chen, and Jing Ai
- 2207** **Gilteritinib Inhibits Glutamine Uptake and Utilization in *FLT3*-ITD-Positive AML**
Megan E. Zavorka Thomas, Xiyuan Lu, Zahra Talebi, Jae Yoon Jeon, Daelynn R. Buelow, Alice A. Gibson, Muhammad Erfan Uddin, Lindsey T. Brinton, Julie Nguyen, Meghan Collins, Alessia Lodi, Shannon R. Sweeney, Moray J. Campbell, Douglas H. Sweet, Alex Sparreboom, Rosa Lapalombella, Stefano Tiziani, and Sharyn D. Baker
- LARGE MOLECULE THERAPEUTICS**
- 2218** **NEI-01-Induced Arginine Deprivation Has Potent Activity Against Acute Myeloid Leukemia Cells Both *In Vitro* and *In Vivo***
Yijun Cai, Jeremy P.H. Chow, Yu-On Leung, Xiaoxu Lu, Chak-Ho Yuen, Wing Lun Lee, Ka-Chun Chau, Liz L. Yang, Raymond M.H. Wong, Justin Y.T. Lam, Daniel T.L. Chow, Steven H.K. Chung, Sui-Yi Kwok, and Yun-chung Leung
- 2228** **Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization**
Samantha Buongervino, Maria V. Lane, Emily Garrigan, Doncho V. Zhelev, Dimiter S. Dimitrov, and Kristopher R. Bosse
- 2240** **Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers**
Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villafior, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, and John H. Strickler
- 2250** **A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway**
Melanie Wurm, Otmar Schaaf, Katharina Reutner, Rajkumar Ganesan, Sven Mostböck, Christina Pelster, Jark Böttcher, Bruna de Andrade Pereira, Christina Taubert, Isabella Alt, Garazi Serna, Aurelie Auguste, Kai B. Stadermann, Denis Delic, Fei Han, Jaume Capdevila, Paolo G. Nuciforo, Rachel Kroe-Barrett, Paul J. Adam, Anne B. Vogt, and Irmgard Hofmann
- 2262** **Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models**
Takuya Kato, Ryuhei Okada, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Hiroshi Fukushima, Peter L. Choyke, and Hisataka Kobayashi
- COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS**
- 2274** **Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible**
Taylor J. Jensen, Aaron M. Goodman, Christopher K. Ellison, Kimberly A. Holden, Shumei Kato, Lisa Kim, Gregory A. Daniels, Kerry Fitzgerald, Erin McCarthy, Prachi Nakashe, Amin R. Mazloom, Eyad Almasri, Graham McLennan, Daniel S. Grosu, Marcia Eisenberg, and Razelle Kurzrock
- TARGETING DRUG RESISTANCE**
- 2280** **Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer**
Austin R. Dosch, Samara Singh, Xizi Dai, Siddharth Mehra, Iago De Castro Silva, Anna Bianchi, Supriya Srinivasan, Zhen Gao, Yuguang Ban, Xi Chen, Sulagna Banerjee, Nagaraj S. Nagathihalli, Jashodeep Datta, and Nipun B. Merchant
- MODELS AND TECHNOLOGIES**
- 2291** **Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer**
Alison R. Mercer-Smith, Wulin Jiang, Juli R. Bago, Alain Valdivia, Morrent Thang, Alex S. Woodell, Stephanie A. Montgomery, Kevin T. Sheets, Carey K. Anders, and Shawn D. Hingtgen
- 2302** **SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy**
Yajing Zhang, Xiaohong Yu, Qiuping Liu, Haiping Gong, An-an Chen, Hongjun Zheng, Shi Zhong, and Yi Li

TABLE OF CONTENTS

ABOUT THE COVER

Vimseltinib is a colony stimulating factor 1 receptor (CSF1R) inhibitor that acts to block both autocrine signaling in tenosynovial giant cell tumor (TGCT) as well as paracrine signaling to inflammatory cells such as macrophages and osteoclasts. Vimseltinib was able to inhibit tumor growth in preclinical models and reduced biomarkers in three initial patients. Read the full study on page 2098.

doi: 10.1158/1535-7163.MCT-20-11-CVR



Molecular Cancer Therapeutics

20 (11)

Mol Cancer Ther 2021;20:2095-2313.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/20/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/20/11>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.